Trends in prescription and cost of Sativex, a cannabinoid-based medicine, in treating patients with multiple sclerosis in England.

Farideh A JavidAnam AlamEmily WilliamsSidhra Sajid MalikUsama MohayuddinSyed Shahzad Hasan

Published in: Journal of pharmaceutical policy and practice (2024)

The results suggested that cannabinoid-based Sativex should be considered an option due to its effectiveness, acceptable tolerance, and safety profile in the prescribing of Sativex.

Keyphrases

primary care
randomized controlled trial
systematic review